logo

FDA Calendar

Share SHARE
Company Name Repligen Corp
Drug Name SecreFlo (NDA)
Event Name FDA decision on SecreFlo for detection of pancreatic duct abnormalities
Event Date 06/21/2012
Outcome Date
Outcome FDA issues complete response letter for SecreFlo (RG1068)
Drug Status
Rival Drugs
Market Potential
Other Approvals
News
Repligen Announces FDA Advisory Committee Date For SecreFlo NDA
Repligen - Eyeing Sustainable Profitability
Repligen Says FDA Cancels Advisory Committee Meeting
Repligen Obtains Complete Response Letter From FDA For RG1068 NDA
Return to FDA Calendar